Publications by authors named "Christine Anne Doyle"
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that boost T-cell ability to identify and attack cancer cells.
- These therapies can cause immune-related adverse events (irAEs), with varying severities ranging from mild (Grade 1-2) to life-threatening (Grade 3-4).
- Due to the long-lasting effects of ICIs, a comprehensive preoperative assessment is essential to manage potential toxicities that can affect any organ system.
